Hastaneye Yatırılan COVID-19 Hastalarında Akciğer Bilgisayarlı Tomografi Parankimal Bulguları ile C Reaktif Protein Arasındaki İlişki

GİRİŞ ve AMAÇ: Bu çalışmada, hastaneye yatışta Toraks Bilgisayarlı Tomografide (BT) COVID-19 pnömonisine ait parankimal bulguların C reaktif protein (CRP) ile ilişkisini araştırmayı amaçladık. YÖNTEM ve GEREÇLER: 1 Nisan-30 Mayıs 2020 tarihleri arasında akciğer tomografisinde akciğer bulguları saptanan ve hastaneye başvuran ardışık 192 COVID-19 hastası çalışmaya dahil edildi. COVID-19 pulmoner bulguları başvuru Toraks BT ile değerlendirildi BULGULAR: 192 hastanın ortanca yaşı 44 (31-59) yıl olup, bunların %46,8'i (90) kadındı. Medyan CRP değeri 15.2mg/L (2.0-55) olarak bulundu. Hastaların Toraks BT bulguları şöyleydi: %69.2 (133) buzlu cam opaklığı, %33.8 (65) konsolidasyon, %6.2 (12) ters halo, %11.9 (23) çılgın kaldırım, %20.8 ( 40) ayrık nodül, %5.7 (11) pulmoner vasküler genişleme, %3.6 (7) bronşektazi ve %17.1 (33) fibrozis ile. Nodül prezentasyonu olmayan hastalarda ortalama CRP 42,8±59,1 nodül prezentasyonu olan hastalarda ise 34,7±53,2 bulundu. CRP ile ilgili bağımsız öngörücüleri belirlemek için; Yukarıda açıklanan göğüs BT parametreleri lineer regresyonda değerlendirildi. Göğüs BT'sinde nodül varlığı (-26.1CI %95; (-49.0,-3.1), p = 0.026), BSTI-CT skoru (20,6, CI %95; 7.6, 33.6, p) arasında istatistiksel olarak anlamlı ilişki saptandı. = 0,002) ve CRP değerleri. TARTIŞMA ve SONUÇ: Çalışmamızda, hastaneye başvuran semptomatik COVID-19 hastalarında nodül gibi atipik bulguları olan hastaların Toraks BT'sinde tipik bulguları olanlara göre CRP düzeylerinin daha düşük olduğunu bulduk.

The Relationship Between Parenchymal Findings of Chest ComputedTomography and C Reactive Protein in COVID-19 Patients at HospitalAdmission

INTRODUCTION: In this study, we aimed to investigate the relationship between the parenchymal findings of COVID-19 pneumonia on chest Coumputed Tomography (CT) and C reactive protein (CRP) at hospital admission. METHODS: 192 consecutive COVID-19 patients with pulmonary findings on chest CT, who were admitted to the hospital between 1st April to 30th May 2020, were included in the study. COVID-19 pulmonary findings were evaluated in admission chest CT RESULTS: Median age of 192 patients was 44 (31-59) years and 46.8% (90) of them were female. Median CRP value was found to be 15.2mg/L (2.0-55). Chest CT findigs of the patients were as follows: 69.2% (133) with ground glass opacity, 33.8% (65) with consolidation, 6.2% (12) with reversed halo, 11.9% (23) with crazy-paving, 20.8% (40) with discrete nodula, 5.7% (11) with pulmonary vascular enlargement, 3.6% (7) with bronchiectasis and 17.1% (33) with fibrosis. The mean CRP was found to be 42.8±59.1 in patients without nodule presentation and 34.7±53.2 in patients with nodule presentation. In order to determine independent predictors related to CRP; chest CT parameters described above were assessed in the linear regression. Association with statisticaly significance were determined between the presence of nodule on chest CT (-26.1CI 95%; (-49.0,-3.1), p = 0.026), BSTI-CT score (20.6, CI 95%; 7.6, 33.6, p= 0.002) and CRP values. DISCUSSION AND CONCLUSION: In our study, we found that patients with atypical findings as nodules had lower CRP levels than those with typical findings on chest CT in symptomatic COVID-19 patients admitted to the hospital.

PDF

___

1. Shah A, Kashyap R, Tosh P, Sampathkumar P, O’Horo JC. Guide to Understanding the 2019 NovelCoronavirus. Mayo Clin Proc. 2020; Apr;95(4):646- 652 https://doi.org/10.1016/j.mayocp.2020.02.003.
2. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and in action. BMJ. 2020;368:m1036. doi: 10.1136/bmj.m1036.
3. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. AnnTranslMed 2020; 2020 Apr;8(7):497.doi: 10.21037/atm.2020.03.157.
4. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RTPCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Aug;296(2):E32-E40.doi: 10.1148/radiol.2020200642.
5. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RTPCR. Radiology 2020 Aug;296(2):E115-E117.doi: 10.1148/radiol.2020200432.
6. Revel M-P, Parkar AP, Prosch H, Silva M, Sverzellati M, Gleeson F, et al. COVID-19 patients and the radiology department–advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). EurRadiol. 2020 Sep;30(9):4903-4909.doi: 10.1007/s00330-020-06865-y.
7. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lungchanges at chest CT during recovery from coronavirus disease 2019 (COVID-19). 2020 Jun;295(3):715-721. doi: 10.1148/radiol.2020200370.
8. Hani C, Trieu NH, Saab I, Dangeard S, Bennani S, Chassagnon G, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imagin 2020 May;101(5):263-268.doi: 10.1016/j.diii.2020.03.014.
9. Wen Z, Chi Y, Zhang L, Liu H, Du K, Li Z, et al. Coronavirus disease 2019: initial detection on chest CT in a retrospective Multicenter study of 103 chinese subjects. Radiology:Cardiothoracic Imaging 2020; 200092. doi.org/10.1148/ryct.2020200092.
10. Inui S, Fujikawa A, Jitsu M, Kunishima N, Watanabe S, Suzuki Y, et al. Chest CT findings in cases from the cruise ship “Diamond Princess” with coronavirus disease 2019 (COVID-19). Radiology Cardiothoracic Imaging. 2020; 200110.doi.org/10.1148/ryct.2020200110
11. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang Pet al. Sensitivity of chest CT for COVID19: Comparison to RTPCR. Radiology. 2020 Aug;296(2):E115-E117.doi: 10.1148/radiol.2020200432.
12. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284:3043–3049
13. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms . Eur J Radiol. 2020 Jun;127:109009. doi: 10.1016/j.ejrad.2020.109009
14. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID19): a pictorial review. Eur Radiol. 2020 Aug;30(8):4381- 4389. doi: 10.1007/s00330-020-06801-0.
15. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America Expert Consensus Stattement on Reporting Chest Ct Findings Reletaed to COVID-19. Endorsed by the Society of Thoracic Radiology, The American College of Radiology and RSNA-Secondary Publication. J Thorac Imaging. 2020 Jul;35(4):219-227. doi: 10.1097/RTI.0000000000000524
16. BSTI. Thoracic imsging in COVID-19 infection. Guidance for the Reporting Radiologist British Society of thoracic imaging. Available at https://www.bsti.org.uk/media/resources/files/BSTI_COVID _19_Radiology_Guidance_version_2_16.03.20.pdf.[Accesse d13April2020]
17. Song FX, Shi NN, Zhang ZY, Shen J, Lu H, Ling Y, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020;200274. doi.org/10.1148/radiol.2020200274
18. Duan YN, Qin J. Pre- and posttreatment chest CT findings: 2019 novel coronavirus (2019-ncov) pneumonia. Radiology. 2020;200323. doi:10.1148/ radiol.2020200323.
19. Pan F, Yan TH, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on Chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020;200370. doi:10.1148/radiol.2020200370
20. Jeffrey K. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. Radiology. 2020;200241. doi:10.1148/radiol.202020024
21. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J (2008) FleischnerSociety: glossary of terms for thoracicimaging. Radiology. 2008 Mar;246(3):697-722. doi: 10.1148/radiol.2462070712.
22. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological find¬ings from 81 patients with COVID-19 pneumo¬nia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434.doi: 10.1016/S1473- 3099(20)30086-4.
23. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 2020;295:200463. Doi: 10.1148/radiol. 2020200463
24. Bekci T. “Reversed halo sign” on 3D CT in COVID-19. Diagn Interv Radiol. 2020 Jul;26(4):379.doi: 10.5152/dir.2020.20254.
25. Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019- nCoV): a study of 63 patients in Wuhan, China. EurRadiol. 2020 Jun;30(6):3306- 3309.doi: 10.1007/s00330-020-06731-x
26. Ai T, Yang Z, Hou H Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RTPCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Aug;296(2):E32-E40. doi: 10.1148/radiol.2020200642.
27. Li X, Zeng X, Liu B, Yu Y. COVID-19 infection presenting with CT halosign. Radiology: CardiothoracicImaging 2020; 200026. doi.org/10.1148/ryct.2020200026
28. Franquet T. Imaging of pulmonary viral pneumonia. Radiology. 2011 Jul;260(1):18-39.doi: 10.1148/radiol.11092149.
29 .Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features. Invest Radiol. 2020 May;55(5):257-261. doi: 10.1097/RLI.0000000000000670.
30. Xiong Y, Sun D, Liu Y, Fan Y, Zhao L, Li X, et al. Clinical and high-resolution CT features of the COVID-19 Infection: Comparison of the initial and follow-up changes. Invest Radiol. 2020 Jun;55(6):332-339. doi: 10.1097/RLI.0000000000000674
31. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 15;19(1):18. doi: 10.1186/s12941-020-00362-2.e clinical and laboratory presentations of primary and secondary glomerular diseases. Ren Fail. 2011;33(8):781-4.
34.Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ, et al. Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine. WMJ. 2016;115(6):317-21.
35.Neale TJ, Ojha PP, Exner M, Poczewski H, Ruger B, Witztum JL, et al. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest. 1994;94(4):1577- 84.
36.O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993;91(1):83-7.
37.Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int. 1993;43(4):918-27.
38.Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol. 1993;4(2):187-94.
39.Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D. Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int. 1992;41(5):1161-9.
40.Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl. 1999;71:S2-5.
41.Galle J, Heermeier K. Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress. Nephrol Dial Transplant. 1999;14(11):2585-9.
42.Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41(3):565-70.
43.Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(6):1908-19.
44.Ruggenenti P, Perna A, Tonelli M, Loriga G, Motterlini N, Rubis N, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual reninangiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol. 2010;5(11):1928-38. https://doi.org/10.4103/ijem.IJEM_183_18